The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis

Guanyu Ruan1 Laboratory of Gynecologic Oncology, Fujian Provincial Maternity and Children’s Hospital, Affiliated Hospital of Fujian Medical University

Lixiang Ye2 Fujian Center for Safety Evaluation of New Drugs, Fujian Medical University

Guifen Liu3 Department of Gynecology, Fujian Provincial Maternity and Children’s Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, People’s Republic of China

Jian An3 Department of Gynecology, Fujian Provincial Maternity and Children’s Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, People’s Republic of China

Jalid Sehouli4 Department of Gynecologic Oncology and Gynecology, Charité Campus Virchow-Klinikum, European Competence Center for Ovarian Cancer, University of Berlin, Berlin, Germany

Pengming Sun1 Laboratory of Gynecologic Oncology, Fujian Provincial Maternity and Children’s Hospital, Affiliated Hospital of Fujian Medical University;3 Department of Gynecology, Fujian Provincial Maternity and Children’s Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, People’s Republic of ChinaCorrespondence[email protected]

Pages 521-528 | Published online: 23 Jan 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin20166611513226808342
PubMed Web of Science ®Google Scholar
SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin20166673026742998
PubMed Web of Science ®Google Scholar
ColemanRLBradyMFHerzogTJBevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialLancet Oncol20171877979128438473
PubMed Web of Science ®Google Scholar
MonkBJMinionLEColemanRLAnti-angiogenic agents in ovarian cancer: past, present, and futureAnn Oncol201627Suppl 1i33i3927141068
PubMed Web of Science ®Google Scholar
GarciaAAHirteHFlemingGPhase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortiaJ Clin Oncol200826768218165643
PubMed Web of Science ®Google Scholar
GraybillWSoodAKMonkBJColemanRLState of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancerGynecol Oncol201513822322626166806
PubMed Web of Science ®Google Scholar
MabuchiSTeraiYMorishigeKMaintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer modelClin Cancer Res2008147781778919047105
PubMed Web of Science ®Google Scholar
MonkBJChoiDCPugmireGBurgerRAActivity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecol Oncol20059690290515721449
PubMed Web of Science ®Google Scholar
MonkBJHanEJosephs-CowanCAPugmireGBurgerRASalvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerGynecol Oncol200610214014416790264
PubMed Web of Science ®Google Scholar
BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol2007255165517118024863
PubMed Web of Science ®Google Scholar
BurgerRABradyMFBookmanMAFlemingGFMonkBJHuangHIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med20113652473248322204724
PubMed Web of Science ®Google Scholar
PerrenTJSwartAMPfistererJA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med20113652484249622204725
PubMed Web of Science ®Google Scholar
Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialJ Clin Oncol2014321302130824637997
PubMed Web of Science ®Google Scholar
AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol2012302039204522529265
PubMed Web of Science ®Google Scholar
MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med20096e100009719621072
PubMed Web of Science ®Google Scholar
HigginsJPAltmanDGGotzschePCThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
PubMed Web of Science ®Google Scholar
DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials198671771883802833
PubMed Web of Science ®Google Scholar
HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ200332755756012958120
PubMed Web of Science ®Google Scholar
AghajanianCGoffBNycumLRWangYVHusainABlankSVFinal overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancerGynecol Oncol2015139101626271155
PubMed Web of Science ®Google Scholar
OzaAMCookADPfistererJStandard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialLancet Oncol20151692893626115797
PubMed Web of Science ®Google Scholar
PovedaAMSelleFHilpertFBevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trialJ Clin Oncol2015333836383826282651
PubMed Web of Science ®Google Scholar
LedermannJAEmbletonACRajaFCediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trialLancet20163871066107427025186
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date